Yuhao Shi

Yuhao Shi.

Yuhao Shi

Yuhao Shi

Residency

Transitional/Brockton-BIDMC, Beth Israel Deaconess Medical Center, Brockton, Mass. Radiation Oncology, New York University School of Medicine, New York, N.Y.

Research Publications Overview

Publications

  • He X, Zhou S, Dolan M, Shi Y, Wang J, Quinn B, Jahagirdar D, Huang WC, Tsuji M, Pili R, Ito F, Ortega J, Abrams SI, Ebos JML, Lovell JF (2021). Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model. Journal for Immunotherapy of Cancer, 9(12), e003101. 
  • Mastri M, Tracz A, Lee CR, Attwood K, Kerbel RS, Dolan M, Shi Y, Ebos JML (2018). ‘Tumor independent host secretomes induced by angiogenesis and immune-checkpoint inhibitors”. Molecular Cancer Therapeutics 17(7):1602-1612.
  • Shi, Y., Bollam, S. R., White, S. M., Laughlin, S. Z., Graham, G. T., Wadhwa, M., ... & Yi, C. (2016). Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression. Developmental Cell, 39(4), 452-465.
  • Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E., Laughlin, S., Wadhwa, M., Chetram, M., Joshi, M., Wang, F., Kallakury, B., Toretsky, J., & Yi, C. (2014). Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Science signaling, 7(324), ra42.

Professional/Educational Meetings/Abstracts

  • Shi Y, Dolan M, Mastri M, Hill JW, Eng K, Ebos JML. (2021) "Targeting type I IFN-regulated secretory profiles to overcome acquired anti-PD-L1 resistance". 112th Annual AACR Meeting, April 10-15, Virtual. 
  • Shi Y, Dolan M, Mastri M, Eng K, Ebos JML. (2020) "Targeting IFNβ-regulated secretory profiles to overcome acquired anti-PD-L1 resistance". Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 10- 5, Virtual. 
  • Shi Y, Mastri M, Dolan M, Oberst M, Ebos JML. (2019) “Intrinsic Tumor Cell Consequences of Acquired Resistance to PD-L1 Blockade”. 110th Annual AACR Meeting, March 19-April 3, Atlanta, GA.
  • Dolan M, Mastri M, Tracz A, Attwood K, Christensen JG, Chatta G, Shi Y, Ebos JML. (2019) “Enhanced efficacy of Sitravatinib (MGCD516) in metastatic models of antiangiogenic therapy resistance”. 110th Annual AACR Meeting, March 19-April 3, Atlanta, GA. 
  • Mastri M, Tracz A, Nguyen T, Shi Y, Bjarnason G, Rini B, Oberst M, Ebos JML. (2017) “Soluble PD-L1 as a surrogate biomarker of metastatic progression and resistance to antiangiogenic therapy” 108th Annual AACR Meeting, April 1-5, Washington DC.
  • Undergraduate Thesis: Shi, Y., Bollam, S., & Yi, C. The role of Rac1 in Nf2 tumorigenesis. (2015)